12. (Amended) ~~A booster immunization~~ The method as claimed in claim 10, ~~in which~~ wherein the vaccine is administered via ~~the~~ deep subcutaneous or intramuscular ~~route~~injection~~, preferably via the intramuscular route in the deltoid region,~~ in one dose or in two doses ~~of said vaccine, preferably of 0.5 ml,~~ at least 1 month apart.

REMARKS

The foregoing amendments were made to conform to the claims to U.S. practice and are not believed to narrow the scope. Accompanying this Preliminary Amendment is a redlined version of the amended claims as well as a clean copy.

If there are any questions or comments regarding this Response or application, the Examiner is encouraged to contact the undersigned attorney as indicated below.

Respectfully submitted,

Date: May 18, 2001

Michael S. Greenfield
Registration No. 37,142

McDonnell Boehnen Hulbert & Berghoff
300 South Wacker Drive
Chicago, IL 60606

Telephone: 312-913-0001
Facsimile: 312-913-0002

U.S. National Phase of PCT/FR99/02913

Redlined Version of Claims

1. (Amended) A vaccine comprising:

– less than 1.2 mg per ml of an aluminum salt, wherein the amount is expressed with respect to the ~~Al^{3+}~~ aluminum atom, and

– immunogenic antigens ~~originating at least from the~~ of poliovirus, ~~from~~ *Corynebacterium diphtheriae* and ~~from~~ *Clostridium tetani*, ~~and~~

~~and~~ wherein the amount of the ~~diphtheria toxoid used as an immunogenic antigen of~~ *Corynebacterium diptheriae* immunogenic antigen ~~of~~ is ~~between~~ 4-16 Lf per ml.

2. (Amended) The vaccine as claimed in claim 1, ~~characterized in that~~ wherein the amount of diphtheria ~~toxoid~~ immunogenic antigen is about 10 Lf per ml.

3. (Amended) The vaccine as claimed in claim 1 ~~or 2~~, ~~in which~~ wherein the amount of tetanus ~~toxoid~~ immunogenic antigen is about 20 Lf per ml.

4. (Amended) The vaccine as claimed in ~~any one of claims 1 to 3~~claim 1, ~~also~~ further comprising at least one antigen ~~chosen~~ selected from the group consisting of *Bordetella pertussis*, hepatitis A and hepatitis B antigens.

9. (Amended) A pharmaceutical kit comprising at least 2 injectable doses of ~~a~~ the vaccine as claimed in ~~one of claims 1 to 4~~claim 1.

10. (Amended) A method for immunizing a human against at least ~~the~~ poliovirus, *Corynebacterium diphtheriae* and *Clostridium tetani*, the method comprising ~~the~~

~~administration of a~~ administering to the person a vaccine as claimed in ~~any one of claims 1 to 4~~claim 1.

11. (Amended) ~~A primary immunization~~ The method as claimed in claim 10, ~~in which~~ wherein the vaccine is administered via ~~the~~ deep subcutaneous or intramuscular ~~route~~injection~~, preferably via the intramuscular route in the deltoid region,~~ in 3 doses ~~of said vaccine, preferably at 0.5 ml~~, the first two doses being administered 1 to 2 months apart~~,~~ and the third dose being administered 6 to 12 months after the injection of the second dose.

12. (Amended) ~~A booster immunization~~ The method as claimed in claim 10, ~~in which~~ wherein the vaccine is administered via ~~the~~ deep subcutaneous or intramuscular ~~route~~injection~~, preferably via the intramuscular route in the deltoid region,~~ in one dose or in two doses ~~of said vaccine, preferably of 0.5 ml,~~ at least 1 month apart.